Shionogi yesterday said it had agreed to pay $1.42bn to buy Sciele Pharma of the US, becoming the latest Japanese drugmaker to acquire an overseas rival.

The move will give the group a chance to broaden its profit base outside its domestic market, where Shionogi and its local rivals are facing government-mandated price cuts and increasing competition from multinational competitors.